A Beloved Classic Just Got Sweeter Than Ever; Candy Crush Solitaire™ Launches Worldwide
6.2.2025 15:00:00 EET | Business Wire | Press release
King, the interactive entertainment company behind the world-famous Candy Crush® franchise, today launches Candy Crush Solitaire™on mobile devices worldwide. Candy Crush Solitaire brings a fresh take to the classic card game, combining the timeless fun of solitaire with the vibrant and colorful world of Candy Crush.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250206977362/en/
Candy Crush Solitaire gameplay (Graphic: King)
Candy Crush Solitaire offers players a fun, mentally stimulating challenge, combining the familiar gameplay of TriPeaks solitaire with challenging levels, innovative gameplay, and tasty rewards, as they are immersed into the sensory and whimsical Candy Crush universe.
Beloved characters join players on a sweet journey around the world, collecting Candified postcards and delicious rewards as they progress through the game, solving puzzles and stacking cards. This new mobile game offering will launch with a set of features, including the “Hold Slot,” enabling players to set cards aside for later use, or they can unleash the fan-favorite Candy Color Bomb booster - reimagined in card form - to conquer tricky levels.
“We’re excited to take a timeless card game like solitaire and reimagine it through the lens of the iconic Candy Crush brand,” said Tjodolf Sommestad, President, King. “The launch of Candy Crush Solitaire marks an important step in King’s strategy to expand our portfolio by combining classic gameplay with our expertise in creating immersive, player-focused mobile experiences. This new addition not only strengthens the Candy Crush franchise’s global reach but also delivers fresh, innovative ways for players to connect and engage with the games they love, all with that signature Candy Crush energy.”
Candy Crush Solitaire builds on the success of Candy Crush Saga, the highest-grossing mobile game of all time in the Western world since its launch [source: Data.ai]. The game has maintained its relevance and reaffirmed its position as one of the global leaders in mobile gaming.
With Candy Crush first captivating players worldwide through Candy Crush Saga, the match-3 mobile gaming phenomenon, the franchise continues to evolve, boasting over 18,000 levels and now expanding into new genres to bring its iconic fun to even more players around the globe.
Since 2023, King has been part of the Microsoft family, and when asked about the most recent solitaire game, Paul Jensen, GM of Casual Games, Microsoft said, “As the most popular card game of all time, Microsoft solitaire is hugely special to us at Microsoft. We’re thrilled to see King create an exciting new twist to solitaire as the newest addition to King’s widely loved Candy Crush franchise. The launch marks an exciting milestone as our businesses look to work together to bring more choice and innovation to the mobile gaming market in the future.”
Candy Crush Solitaire is free to download and available now on the Amazon App Store, Apple App Store, Google Play, Samsung Galaxy Store and more.
About King
With a mission of Making the World Playful, King is a leading interactive entertainment company with more than 20 years of history of delivering some of the world’s most iconic games in the mobile gaming industry, including the world-famous Candy Crush franchise, as well as other mobile game hits such as Farm Heroes Saga. King games are played by more than 200 million monthly active users. King, part of Microsoft (NASDAQ: MSFT), has Kingsters in Stockholm, Malmö, London, Barcelona, Berlin, Dublin, San Francisco, New York, Los Angeles and Malta. More information can be found at King.com or by following us on LinkedIn, @lifeatking on Instagram, or @king_games on X.
About Candy Crush Solitaire
Candy Crush Solitaire™ brings a fresh twist to the classic card game, combining the timeless fun of solitaire with the vibrant and colorful world of Candy Crush®. Players can unwind and challenge themselves as they solve puzzles, stack cards, and enjoy innovative gameplay that reimagines solitaire in a delightful new way.
Candy Crush Solitaire is free to download and available on the Apple App Store, Google Play, and Amazon App Store. Whether you’re a fan of card games or looking for a relaxing escape, Candy Crush Solitaire offers a fun and engaging experience for players of all ages.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250206977362/en/
Contacts
Global Media Contact: kingcomms@king.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 12:18:00 EEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom